- Report
- January 2024
- 168 Pages
Global
€4563EUR$4,995USD£3,891GBP
- Report
- July 2023
- 210 Pages
Global
From €4111EUR$4,500USD£3,505GBP
- Report
- November 2020
- 450 Pages
Global
From €4476EUR$4,900USD£3,817GBP
- Report
- October 2020
- 85 Pages
Global
€20097EUR$22,000USD£17,137GBP
- Drug Pipelines
- September 2019
- 141 Pages
Global
€9135EUR$10,000USD£7,790GBP
- Report
- November 2018
- 80 Pages
Global
From €2741EUR$3,000USD£2,337GBP
- Report
- October 2023
- 100 Pages
Global
From €3500EUR$4,104USD£3,089GBP
- Report
- October 2023
- 99 Pages
Global
From €3500EUR$4,104USD£3,089GBP
- Report
- May 2023
- 73 Pages
Global
From €3500EUR$4,104USD£3,089GBP
- Report
- May 2022
- 65 Pages
Global
From €3197EUR$3,500USD£2,726GBP
- Report
- November 2021
- 747 Pages
Global
From €3654EUR$4,000USD£3,116GBP
- Report
- December 2023
- 248 Pages
Global
From €2283EUR$2,499USD£1,947GBP
€3261EUR$3,570USD£2,781GBP
- Book
- November 2024
- 464 Pages
- Book
- March 2024
- 496 Pages
- Book
- August 2022
- 320 Pages
- Book
- April 2020
- 320 Pages
- Book
- February 2020
- 202 Pages

Immune Checkpoint Inhibitor drugs are a type of immunotherapy used to treat immune disorders. They work by blocking proteins that act as “checkpoints” in the immune system, allowing the body to recognize and attack cancer cells. These drugs are used to treat a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer. They are also used to treat autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn’s disease.
Immune Checkpoint Inhibitor drugs are a relatively new form of treatment, and the market is still in its early stages. However, the potential of these drugs has led to a surge in research and development, with many companies investing in the development of new drugs.
Some of the major companies in the Immune Checkpoint Inhibitor market include Bristol-Myers Squibb, Merck, AstraZeneca, Roche, and Novartis. Other companies such as Pfizer, AbbVie, and Johnson & Johnson are also involved in the development of these drugs. Show Less Read more